GlassScriptPhysician profile
Ibrahim Yazji
NPI 1609106020
$939.86
in general payments reported to CMS, 2019-2025
9 companies · $247 in 2025
The $247 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.16 · 2020: $347 · 2022: $39.80 · 2024: $272 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $518.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $384.76 | 2024-2025 | Corevalve Evolut R |
| Artivion, INC. | $322.80 | 2020 | |
| Atricure, INC. | $86.38 | 2024-2025 | Synergy Ablation System, Atricure Cryoice Cryosphere Cryoablation System, Atriclip Laa Exclusion System |
| Mannkind Corporation | $34.16 | 2019 | |
| Edwards Lifesciences Corporation | $27.53 | 2024 | Mitris Resilia Mitral Valve |
| Outset Medical INC | $24.66 | 2020 | |
| Abiomed | $20.95 | 2022 | |
| Smith+Nephew, INC. | $19.77 | 2024 | Pico 7 |
| Merck Sharp & Dohme LLC | $18.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Yazji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.